CN1133047A - 治疗用肽衍生物 - Google Patents
治疗用肽衍生物 Download PDFInfo
- Publication number
- CN1133047A CN1133047A CN94193717A CN94193717A CN1133047A CN 1133047 A CN1133047 A CN 1133047A CN 94193717 A CN94193717 A CN 94193717A CN 94193717 A CN94193717 A CN 94193717A CN 1133047 A CN1133047 A CN 1133047A
- Authority
- CN
- China
- Prior art keywords
- peptide
- phe
- cys
- thr
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
- C07K7/086—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Description
分子量测试 | 分子量计算 | IC50 nM | |
SRIF-14 | - | - | 0.17 |
SRIF-28 | - | - | 0.23 |
BIM-23107 | 1340.4 | 1340.40 | 0.30 |
BIM-23118 | 1313.5 | 1313.52 | 0.30 |
BIM-23135 | 1426.2 | 1426.64 | 2.52 |
BIM-23158 | 1299.6 | 1299.54 | 0.33 |
BIM-23167 | 1347.6 | 1347.55 | 0.09 |
BIM-23173 | 1235.5 | 1235.46 | 0.11 |
BIM-23179 | 1305.9 | 1305.55 | 0.12 |
BIM-23181 | 1435.0 | 1434.62 | 0.25 |
BIM-23182 | 1193.8 | 1193.42 | 0.12 |
BIM-23183 | 1323.0 | 1322.49 | 0.22 |
BIM-23190 | 1202.8 | 1202.47 | 0.20 |
BIM-23191 | 1314.9 | 1314.61 | 0.08 |
BIM-23195 | 1150.8 | 1150.39 | 0.08 |
BIM-23196 | 1243.7 | 1243.50 | 0.09 |
BIM-23197 | 1252.7 | 1252.55 | 0.29 |
BIM-23201 | 1262.8 | 1262.53 | 0.14 |
BIM-23202 | 1247.0 | 1246.53 | 0.18 |
2小时 | 4小时 | 6小时 | 8小时 | |
BIM-23060 | 86.39 | 64.96 | 47.62 | 38.15 |
BIM-23167 | 92.67 | 79.54 | 59.72 | 50.14 |
BIM-23179 | 92.79 | 63.85 | 67.78 | 68.26 |
BIM-23181 | 99.24 | 77.07 | 60.56 | 56.12 |
2小时 | 4小时 | 6小时 | 8小时 | |
BIM-23023 | 0.48 | 1.11 | 2.26 | 4.32 |
BIM-23190 | 0.68 | 0.57 | 0.76 | 1.04 |
BIM-23195 | 1.19 | 3.13 | 2.08 | 3.23 |
BIM-23197 | 1.01 | 0.59 | 1.14 | 1.59 |
细胞生长(对照的百分数)1 | |
SRIF-14 | 91.3 |
SRIF-28 | 98.0 |
BIM-23014C | 74.1 |
BIM-23107 | 67.5 |
BIM-23109 | 72.1 |
BIM-23118 | 61.0 |
BIM-23135 | 62.9 |
BIM-23167 | 60.2 |
BIM-23173 | 67.9 |
BIM-23181 | 69.1 |
BIM-23182 | 68.7 |
BIM-23183 | 69.1 |
BIM-23195 | 69.2 |
BIM-23197 | 66.4 |
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10419493A | 1993-08-09 | 1993-08-09 | |
US08/104194 | 1993-08-09 | ||
US08/104,194 | 1993-08-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1133047A true CN1133047A (zh) | 1996-10-09 |
CN1055700C CN1055700C (zh) | 2000-08-23 |
Family
ID=22299154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94193717A Expired - Fee Related CN1055700C (zh) | 1993-08-09 | 1994-08-08 | 治疗用肽衍生物 |
Country Status (30)
Country | Link |
---|---|
US (1) | US5552520A (zh) |
EP (3) | EP1288224B1 (zh) |
JP (3) | JP3618750B2 (zh) |
KR (1) | KR100325972B1 (zh) |
CN (1) | CN1055700C (zh) |
AT (3) | ATE284413T1 (zh) |
AU (1) | AU689490B2 (zh) |
CA (1) | CA2168113C (zh) |
CZ (3) | CZ292586B6 (zh) |
DE (3) | DE69435105D1 (zh) |
DK (3) | DK1288223T3 (zh) |
ES (3) | ES2196031T3 (zh) |
FI (1) | FI960584A (zh) |
GE (1) | GEP20002146B (zh) |
HK (2) | HK1053313A1 (zh) |
HU (1) | HU224350B1 (zh) |
LT (1) | LT4078B (zh) |
LV (1) | LV11549B (zh) |
MD (1) | MD1591B2 (zh) |
NZ (1) | NZ271238A (zh) |
PL (1) | PL180612B1 (zh) |
PT (2) | PT1288223E (zh) |
RO (1) | RO117259B1 (zh) |
RU (1) | RU2133252C1 (zh) |
SG (1) | SG75092A1 (zh) |
SI (2) | SI9420051A (zh) |
SK (1) | SK15096A3 (zh) |
UA (1) | UA44707C2 (zh) |
WO (1) | WO1995004752A1 (zh) |
ZA (1) | ZA945966B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011147138A1 (zh) * | 2010-05-28 | 2011-12-01 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
CN108659100A (zh) * | 2017-03-28 | 2018-10-16 | 上海新生源医药集团有限公司 | 具有镇痛作用的多肽及其应用 |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
CA2190633A1 (en) * | 1995-03-20 | 1996-09-26 | Kenji Shibata | Novel calcitonin derivatives |
US5824772A (en) * | 1995-04-04 | 1998-10-20 | Advanced Bioconcept, Inc. | Fluorescent somatostatin |
US7048906B2 (en) | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
US6861053B1 (en) | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US6479457B2 (en) | 1995-06-06 | 2002-11-12 | Kinerton Limited | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
US5830431A (en) * | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
US7410948B2 (en) | 1995-07-13 | 2008-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Analogs of parathyroid hormone |
US6544949B1 (en) | 1995-07-13 | 2003-04-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Analogs of parathyroid hormone |
US5766620A (en) * | 1995-10-23 | 1998-06-16 | Theratech, Inc. | Buccal delivery of glucagon-like insulinotropic peptides |
US7078413B2 (en) | 1996-04-19 | 2006-07-18 | Wisconsin Alumni Research Foundation | Compositions and methods of use for a bombesin peptide |
US6492330B1 (en) * | 1996-08-16 | 2002-12-10 | National Institute Of Immunology | Antiangiogenic drugs |
US5968903A (en) * | 1998-05-07 | 1999-10-19 | Biomeasure, Incorporated | Inhibition of H. pylori proliferation |
US6124263A (en) * | 1998-11-16 | 2000-09-26 | Asta Medica Ag | Treatment of tumors by administration of growth hormone releasing compounds and their antagonists |
US6864234B1 (en) | 1999-06-25 | 2005-03-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Somatostatin agonists |
HUP0201696A3 (en) * | 1999-06-25 | 2002-10-28 | Sod Conseils Rech Applic | Cyclic peptides, pharmaceutical compositions comprising thereof and their use |
IES990700A2 (en) | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
AU2004200688B2 (en) * | 1999-08-18 | 2007-01-25 | Ipsen Pharma S.A.S. | Sustained release formulation of a peptide |
EP1348444B1 (en) * | 1999-08-18 | 2006-04-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Sustained release formulation of a peptide complexed with a polymer |
US7109166B1 (en) | 1999-08-18 | 2006-09-19 | Societe De Conseils De Recherches Et D'applications Scientifiques, Sas | Sustained release formulation of a peptide |
ES2209948T3 (es) * | 1999-08-18 | 2004-07-01 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Formulacion de un peptico de liberacion sostenida. |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
US6316414B1 (en) | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
MD2074G2 (ro) * | 2000-12-29 | 2003-06-30 | Юрий НИКИТИН | Procedeu şi instalaţie de captare a vaporilor de carburant la staţiile de alimentare cu petrol, condensator al vaporilor de carburant utilizat în instalaţia menţionată |
ES2284859T3 (es) | 2001-03-06 | 2007-11-16 | Il Consorzio Ferrara Richerche | Procedimiento para modular la proliferacion de celulas de carcinoma medular tiroideo. |
ATE394114T1 (de) * | 2001-03-08 | 2008-05-15 | Univ Tulane | Somatostatin-antagonisten |
US20030229013A1 (en) * | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
FR2833596B1 (fr) * | 2001-12-14 | 2005-02-18 | Aventis Pharma Sa | Procede de preparation de derives d'echinocandine |
US20040171070A1 (en) * | 2002-05-20 | 2004-09-02 | Ramagauri Bhikhabhai | Peptide analysis using a solid support |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
US7186692B2 (en) | 2002-12-17 | 2007-03-06 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |
EP1581245A2 (en) | 2002-12-17 | 2005-10-05 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity |
US7229966B2 (en) | 2002-12-17 | 2007-06-12 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US20090220587A1 (en) * | 2005-02-01 | 2009-09-03 | United State Army | Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands |
US7741431B2 (en) * | 2005-02-01 | 2010-06-22 | The United States Of America As Represented By The Secretary Of The Army | Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof |
JP4879988B2 (ja) | 2005-09-29 | 2012-02-22 | メルク・シャープ・エンド・ドーム・コーポレイション | メラノコルチン−4受容体モジュレーターとしてのアシル化スピロピペリジン誘導体 |
CA2770486C (en) | 2006-09-22 | 2014-07-15 | Merck Sharp & Dohme Corp. | Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
PT2118123E (pt) | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
ES2614990T3 (es) | 2008-06-12 | 2017-06-02 | Ipsen Bioinnovation Limited | Proteínas de fusión para uso en el tratamiento de acromegalia |
WO2009150470A2 (en) | 2008-06-12 | 2009-12-17 | Syntaxin Limited | Suppression of cancers |
GB0820970D0 (en) | 2008-11-17 | 2008-12-24 | Syntaxin Ltd | Suppression of cancer |
WO2010107486A2 (en) * | 2009-03-18 | 2010-09-23 | The Board Of Trustees Of The Leland Stanford Junior University | Use of somatostatin or an analogue thereof in combination with external radiation therapy |
SI2462246T1 (en) | 2009-09-28 | 2018-01-31 | Intarcia Therapeutics, Inc. | Fast-setting and / or cessation of substantially unchanged delivery of the product |
BR112012012945A2 (pt) | 2009-11-25 | 2020-12-29 | Arisgen Sa | Composição de liberação mucosal, seu método de produção, complexo de peptídeo pré-formado, kit e uso de um agente ativo de peptídeo |
TWI536999B (zh) | 2010-01-13 | 2016-06-11 | 艾普森藥品公司 | 製備持續釋放生長激素抑制素類似物之醫藥組成物之方法 |
EP2399931A1 (fr) * | 2010-06-22 | 2011-12-28 | Ipsen Pharma S.A.S. | Nouveaux composés octapeptidiques et leur utilisation thérapeutique |
PT2603600T (pt) | 2010-08-13 | 2019-02-27 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos |
CA2852468A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
CA2864120A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
RU2017145921A (ru) | 2012-02-15 | 2019-02-21 | Эйлерон Терапьютикс, Инк. | Пептидомиметические макроциклы |
BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
SG11201702223UA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
BR112017019738A2 (pt) | 2015-03-20 | 2018-05-29 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
SG10201913699QA (en) | 2016-05-16 | 2020-03-30 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
WO2020077129A1 (en) | 2018-10-11 | 2020-04-16 | Intarcia Therapeutics, Inc. | Human amylin analog polypeptides and methods of use |
KR20220017695A (ko) * | 2020-08-05 | 2022-02-14 | 주식회사 레미바이오 | 아스코르브산 유도체 및 이를 포함하는 조성물 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1246055A (en) * | 1980-03-24 | 1988-12-06 | Joseph H. Cort | N-.omega.-substituted hormonogens of vasopressin and its synthetic analogs |
DE3522638A1 (de) * | 1985-06-25 | 1987-01-08 | Diamalt Ag | Neue somatostatin-derivate |
DE3614833A1 (de) | 1986-01-16 | 1987-07-23 | Hoechst Ag | Peptide mit vasorelaxierender, natriuretischer und diuretischer wirkung, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
NL194729C (nl) * | 1986-10-13 | 2003-01-07 | Novartis Ag | Werkwijze voor de bereiding van peptidealcoholen via vaste fase. |
DK163689A (da) * | 1988-04-08 | 1989-10-30 | Sandoz Ag | Peptidderivater |
ZA895838B (en) | 1988-08-18 | 1991-03-27 | Syntex Inc | Pharmaceutical compounds |
BE1003762A3 (fr) | 1988-11-11 | 1992-06-09 | Sandoz Sa | Nouvelle utilisation therapeutique de la somatostatine et de ses analogues et derives. |
DE69024230T2 (de) * | 1989-12-22 | 1996-05-02 | Commw Scient Ind Res Org | An fette gebundene aminosäuren, peptide oder deren derivate |
GB9209032D0 (en) * | 1992-04-25 | 1992-06-10 | Ciba Geigy Ag | New peptide derivatives |
-
1994
- 1994-08-08 JP JP50654195A patent/JP3618750B2/ja not_active Expired - Lifetime
- 1994-08-08 DK DK02026862T patent/DK1288223T3/da active
- 1994-08-08 CN CN94193717A patent/CN1055700C/zh not_active Expired - Fee Related
- 1994-08-08 NZ NZ271238A patent/NZ271238A/en not_active IP Right Cessation
- 1994-08-08 SG SG1996005779A patent/SG75092A1/en unknown
- 1994-08-08 ES ES94924590T patent/ES2196031T3/es not_active Expired - Lifetime
- 1994-08-08 WO PCT/US1994/008875 patent/WO1995004752A1/en active IP Right Grant
- 1994-08-08 AT AT02026862T patent/ATE284413T1/de not_active IP Right Cessation
- 1994-08-08 RU RU96104340A patent/RU2133252C1/ru not_active IP Right Cessation
- 1994-08-08 GE GEAP19943038A patent/GEP20002146B/en unknown
- 1994-08-08 MD MD96-0137A patent/MD1591B2/ro unknown
- 1994-08-08 EP EP02026863A patent/EP1288224B1/en not_active Expired - Lifetime
- 1994-08-08 ES ES02026863T patent/ES2309131T3/es not_active Expired - Lifetime
- 1994-08-08 EP EP94924590A patent/EP0788509B1/en not_active Expired - Lifetime
- 1994-08-08 DE DE69435105T patent/DE69435105D1/de not_active Expired - Lifetime
- 1994-08-08 DK DK94924590T patent/DK0788509T3/da active
- 1994-08-08 AT AT94924590T patent/ATE241643T1/de not_active IP Right Cessation
- 1994-08-08 DE DE69432758T patent/DE69432758T2/de not_active Expired - Lifetime
- 1994-08-08 EP EP02026862A patent/EP1288223B1/en not_active Expired - Lifetime
- 1994-08-08 HU HU9600281A patent/HU224350B1/hu not_active IP Right Cessation
- 1994-08-08 PT PT02026862T patent/PT1288223E/pt unknown
- 1994-08-08 DE DE69434181T patent/DE69434181T2/de not_active Expired - Lifetime
- 1994-08-08 ES ES02026862T patent/ES2229045T3/es not_active Expired - Lifetime
- 1994-08-08 DK DK02026863T patent/DK1288224T3/da active
- 1994-08-08 KR KR1019960700664A patent/KR100325972B1/ko not_active IP Right Cessation
- 1994-08-08 PL PL94312989A patent/PL180612B1/pl not_active IP Right Cessation
- 1994-08-08 SI SI9420051A patent/SI9420051A/sl unknown
- 1994-08-08 UA UA96020456A patent/UA44707C2/uk unknown
- 1994-08-08 CA CA002168113A patent/CA2168113C/en not_active Expired - Fee Related
- 1994-08-08 SI SI9430451T patent/SI0788509T1/xx unknown
- 1994-08-08 SK SK150-96A patent/SK15096A3/sk unknown
- 1994-08-08 PT PT94924590T patent/PT788509E/pt unknown
- 1994-08-08 RO RO96-00225A patent/RO117259B1/ro unknown
- 1994-08-08 AT AT02026863T patent/ATE399177T1/de not_active IP Right Cessation
- 1994-08-08 AU AU74819/94A patent/AU689490B2/en not_active Ceased
- 1994-08-08 CZ CZ1996390A patent/CZ292586B6/cs not_active IP Right Cessation
- 1994-08-09 US US08/287,957 patent/US5552520A/en not_active Expired - Lifetime
- 1994-08-09 ZA ZA945966A patent/ZA945966B/xx unknown
-
1996
- 1996-02-08 FI FI960584A patent/FI960584A/fi not_active Application Discontinuation
- 1996-03-06 LT LT96-025A patent/LT4078B/lt not_active IP Right Cessation
- 1996-03-08 LV LVP-96-71A patent/LV11549B/en unknown
-
2000
- 2000-03-22 CZ CZ20001032A patent/CZ289590B6/cs not_active IP Right Cessation
- 2000-03-22 CZ CZ20001033A patent/CZ289552B6/cs not_active IP Right Cessation
-
2003
- 2003-08-04 HK HK03105591A patent/HK1053313A1/xx not_active IP Right Cessation
- 2003-08-04 HK HK03105592A patent/HK1053314A1/xx not_active IP Right Cessation
-
2004
- 2004-08-12 JP JP2004235535A patent/JP3785179B2/ja not_active Expired - Lifetime
- 2004-08-12 JP JP2004235503A patent/JP3869439B2/ja not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011147138A1 (zh) * | 2010-05-28 | 2011-12-01 | 山东先声麦得津生物制药有限公司 | 靶向性白细胞介素融合蛋白及其制备方法与应用 |
CN108659100A (zh) * | 2017-03-28 | 2018-10-16 | 上海新生源医药集团有限公司 | 具有镇痛作用的多肽及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1055700C (zh) | 治疗用肽衍生物 | |
CN1156492C (zh) | 抑生长素肽 | |
CN1052730C (zh) | 具有生长激素释放特性的化合物 | |
CN1129606C (zh) | 七肽催产素类似物 | |
CN1521189A (zh) | 甲状旁腺素类似物 | |
CN1137136C (zh) | 定向细胞毒性蒽环型类似物 | |
CN1129224A (zh) | 类胰高血糖素促胰岛素的多肽类似物组合物及其使用方法 | |
FI104253B (fi) | Menetelmä terapeuttisesti käyttökelpoisten nonapeptidibombesiiniantagonistien valmistamiseksi | |
CN1154657C (zh) | 抑生长素的环肽类似物 | |
CN1124927A (zh) | Yy肽类似物及其应用 | |
CN1187199A (zh) | 新的多拉抑放素衍生物及其制备方法和用途 | |
CN1161374C (zh) | 环肽 | |
KR20140100937A (ko) | 펩티도미메틱 거대고리 | |
CN1181096C (zh) | 环六肽抑生长素类似物 | |
CN1422278A (zh) | kahalalide F及相关化合物 | |
CN1032795A (zh) | 具有优越效能的α-黑素细胞刺激激素片段的线状和环状类似物 | |
EP2314616A1 (en) | Peptidic GLP-2 agonists | |
AU6751290A (en) | Synthetic calcitonin peptides | |
CN1034663C (zh) | 血液调节肽的制备方法 | |
CN1852742A (zh) | 具有抑制生长激素释放活性的促生长素抑制素类似物 | |
CN1382154A (zh) | 具有nk2拮抗剂作用的碱性单环化合物,其制备方法,和含有它们的制剂 | |
CN1051914A (zh) | 肽类 | |
CN1061605A (zh) | 促黄体生成素释放激素拮抗类似物的合成方法、产品及应用 | |
CN1119650A (zh) | 具有胃肠道运动刺激活性的胃动素样多肽 | |
CN1876677A (zh) | 新型lhrh拮抗剂,其制备方法和药物用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: PROPOSAL AND SCIENCE EXECUTION CO.,LTD. Free format text: FORMER OWNER: BIOMEASURE INC. Effective date: 20030314 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20030314 Address after: France Patentee after: Sod Conseils Rech Applic Address before: Massachusetts, USA Patentee before: Biomeasure Inc. |
|
C56 | Change in the name or address of the patentee |
Owner name: IPSEN MEDICINE CO.,LTD. Free format text: FORMER NAME: PROPOSAL AND SCIENCE EXECUTION CO.,LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: France Patentee after: Ipsen Pharma Address before: France Patentee before: Sod Conseils Rech Applic |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: France 92650 - Boulogne Billancourt, Georges Plantagenet pier No. 65 Patentee after: Ipsen Pharma Address before: France Patentee before: Ipsen Pharma |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20000823 Termination date: 20090808 |